|By PR Newswire||
|August 28, 2014 08:40 AM EDT||
NEW YORK, Aug. 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
GBI Research has released the pharma report, "ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations" Changes in diagnostic criteria have reduced the symptom threshold for diagnosis and finally bring the acceptance of adult ADHD to the clinical setting, enabling those previously unable to obtain a diagnosis to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed to suffer from ADHD, 41.3% of these cases are classified as severe and would be eligible for therapeutic intervention.
The current ADHD therapeutics market is flooded with generics and dominated by the use of Extended-Release (ER) stimulant drugs which have superseded short-acting, Immediate-Release (IR) formulations. With dose titration per patient, ER stimulants are usually effective in 70-90% of patients. However, all stimulants apart from Vyvanse come with potential for abuse. Non-stimulants are used for those who are poor-responders, have poor cardiac history or prefer non-stimulant medication however their efficacy is lacking in comparison. Currently, 10% of adult patients are using a combination of ER and IR treatment for an additional duration, representing an unmet need within this growing ADHD segment.
The current developmental pipeline addresses these gaps in the market, with three potential non-stimulants entering the market during the forecast period and SHP465, which aims to address the unmet need in the adult ADHD segment with its tailored duration of action. In spite of anticipated drug approvals, patents expirations and increased generic competition will cause ACoT to remain fairly static and even decrease across some nations.
As a result, the global market is not expected to be driven by drug approvals, but primarily by a growing prevalence, increase in rates of diagnosis, and therefore eligible treatment population. Global market revenues are forecast to rise at a CAGR of 4.8% to $9.4 billion by 2020.
The report analyzes the incidence of ADHD, current options for its treatment, pipeline, market forecasts and deals surrounding ADHD therapeutics.The report covers and includes -
- A brief introduction into ADHD, symptoms, diagnosis, epidemiology, etiology, pathophysiology, economic implications of their treatment and the current treatment options for the condition.
- An analysis of the currently marketed ADHD drugs, including recent sales figures, safety and efficacy data of the drugs and a discussion of the likely performance of each drug within the forecast period.
- Comprehensive reviews of the pipeline for ADHD drugs, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type and mechanism of action.
- Additional statistical analysis of clinical trial duration, size and attrition rate by phase and mechanism of action.
- An in-depth, multi-scenario forecast model for the ADHD drugs market in the US, Canada, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated performance of both marketed drugs and any expected to be approved within the forecast period, and takes into account drug cost, patent expiration, efficacy, safety and likely prescription volumes.
- A detailed discussion of drivers and barriers for the ADHD market
- An in-depth analysis of licensing and co-development deals involving drugs indicated in ADHD, including an in-depth outline of key deals.
Reasons to buy
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
- Understand the key signaling pathways and molecular targets currently under investigation in drug development for ADHD.
- Gain an in-depth view of the current status of the ADHD therapeutics pipeline, including the most common molecule types and molecular targets in development.
- Observe trends in clinical trial duration and size amongst clinical phases and mechanisms of action, and use the clinical trial attrition rate analysis to assess the risk profiles of current and/or future developmental programs for ADHD therapeutics.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ADHD therapeutics market.
- Analyze current and past deals surrounding ADHD therapeutics, including their value, year of deal and in-depth details of key deals within the ADHD market.
1 Table of Contents
1 Table of Contents 4
2 Introduction 8
2.1 Disease Introduction 8
2.2 Symptoms 9
2.3 Epidemiology 9
2.4 Etiology 10
2.5 Pathophysiology 11
2.5.1 Diagnosis Rating Scales 14
2.5.2 DSM-5 Criteria for ADHD 15
2.5.3 ICD-10 Criteria for Hyperkinetic Disorder 17
2.6 Treatment 18
2.6.1 Treatment Algorithm 19
3 Marketed Products 20
3.1 Stimulant Drugs 21
3.1.1 Adderall XR – Shire 21
3.1.2 Concerta – Janssen Pharmaceuticals 22
3.1.3 Daytrana – Noven Pharmaceuticals 23
3.1.4 Focalin XR – Novartis 25
3.1.5 Ritalin LA – Novartis 26
3.1.6 Provigil – Teva Pharmaceutical 26
3.1.7 Quillivant XR– Pfizer Pharmaceuticals 27
3.1.8 Vyvanse – Shire 28
3.2 Non-stimulant Drugs 29
3.2.1 Strattera – Eli Lilly 29
3.2.2 Intuniv – Shire 30
3.2.3 Kapvay – Concordia Pharmaceuticals 31
3.3 Comparative Efficacy and Safety 32
4 ADHD Pipeline 34
4.1 Overview 34
4.2 Mechanisms of Action in the Pipeline 36
4.3 Clinical Trials 39
4.3.1 Attrition Rate 39
4.3.2 Clinical Trial Duration 41
4.3.3 Clinical Trial Size 43
4.3.4 Comparative Clinical Trial Metrics Analysis 46
4.3.5 SHP465 – Shire 47
4.3.6 NT-0202 – Neos Therapeutics 47
4.3.7 Edivoxetine – Eli Lilly 48
4.3.8 NWP09 – Pfizer 49
4.3.9 NT-0102 – Neos Therapeutics 50
4.3.10 Metadoxine ER – Alcobra 50
4.3.11 SPN-812 – Supernus Pharmaceuticals 51
4.3.12 Dextroamphetamine Transdermal – Noven Pharmaceuticals 52
4.4 Comparative Efficacy and Safety 53
5 Market Forecast to 2020 56
5.1 Global Market 57
5.2 North America 60
5.2.1 Treatment Usage Patterns 60
5.2.2 Annual Cost of Treatment 61
5.2.3 Market Size 62
5.3 Leading Five EU Countries (EU5) 63
5.3.1 Treatment Usage Patterns 63
5.3.2 Annual Cost of Treatment 64
5.3.3 Market Size 65
5.4 Japan 66
5.4.1 Treatment Usage Patterns 66
5.4.2 Annual Cost of Treatment 66
5.4.3 Market Size 66
5.5 Drivers and Barriers 68
5.5.1 Drivers 68
5.5.2 Barriers 69
6 Deals and Strategic Consolidations 70
6.1 Overview 70
6.2 Co-development Deals 72
7 Appendix 75
7.1 Market Definition 80
7.2 Abbreviations 80
7.3 References 81
7.4 Research Methodology 86
7.4.1 Secondary Research 87
7.4.2 Marketed Product Profiles 87
7.4.3 Late-Stage Pipeline Candidates 88
7.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 88
7.4.5 Product Competitiveness Framework 88
7.4.6 Pipeline Analysis 88
7.4.7 Forecasting Model 89
7.4.8 Deals Data Analysis 90
7.5 Contact Us 90
7.6 Disclaimer 91
1.1 List of Tables
Table 1: Common Assessment Scales Used to Aid ADHD Diagnosis 14
Table 2: DSM-5 Criteria for Attention Deficit Hyperactivity Disorder 15
Table 3: ICD-10 Criteria for Attention Deficit Hyperactivity Disorder 17
Table 4: ADHD Therapeutics Market, Global, Pipeline, Discovery, 2014 75
Table 5: ADHD Therapeutics Market, Global, Pipeline, Preclinical, 2014 75
Table 6: ADHD Therapeutics Market, Global, Pipeline, Phase I, 2014 75
Table 7: ADHD Therapeutics Market, Global, Pipeline, Phase II, 2014 76
Table 8: ADHD Therapeutics Market, Global, Pipeline, Phase III, 2014 76
Table 9: ADHD Theapeutics Market, Global, Pipeline, Pre-Registration, 2014 76
Table 10: ADHD Therapeutics Market, Global, Market Forecast, 2013-2020 77
Table 11: ADHD Therapeutics Market, US, Market Forecast, 2013-2020 77
Table 12: ADHD Therapeutics Market, Canada, Market Forecast, 2013-2020 78
Table 13: ADHD Therapeutics Market, UK, Market Forecast, 2013-2020 78
Table 14: ADHD Therapeutics Market, France, Market Forecast, 2013-2020 78
Table 15: ADHD Therapeutics Market, Germany, Market Forecast, 2013-2020 79
Table 16: ADHD Therapeutics Market, Italy, Market Forecast, 2013-2020 79
Table 17: ADHD Therapeutics Market, Spain, Market Forecast, 2013-2020 79
Table 18: ADHD Therapeutics Market, Japan, Market Forecast, 2013-2020 79
1.2 List of Figures
Figure 1: ADHD Treatment Algorithm 19
Figure 2: ADHD Therapeutics Market, Marketed Products, Heat Map, 2013 33
Figure 3: ADHD Therapeutics Market, Global, Pipeline (%), 2013 35
Figure 4: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action and Program Type, 2013 36
Figure 5: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action (Tier 1) and Stage of Development, 2013 37
Figure 6: ADHD Therapeutics Market, Global, Pipeline Distribution by Mechanism of Action (Tier 2) and Stage of Development, 2013 38
Figure 7: ADHD Therapeutics Market, Global, Pipeline, Attrition Rate (%), 2013 40
Figure 8: ADHD Therapeutics Market, Global, Attrition Rate by Mechanism of Action (%), 2013 41
Figure 9: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Duration (months), 2013 42
Figure 10: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism (months), 2013 43
Figure 11: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013 44
Figure 12: ADHD Therapeutics Market, Global, Pipeline, Clinical Trial Size per Product by Mechanism of Action, 2013 45
Figure 13: ADHD Therapeutics Market, Global, Pipeline, Size by Clinical Trial by Mechanism of Action, 2013 46
Figure 14: ADHD Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2013 47
Figure 15: ADHD Therapeutics Market, Global, Sales Forecast for Edivoxetine ($m), 2016–2020 49
Figure 16: ADHD Therapeutics Market, Global, Sales Forecast for Metadoxine ER ($m), 2017–2020 51
Figure 17: ADHD Therapeutics Market, Global, Sales Forecast for SPN-812 ($m), 2019–2020 52
Figure 18: ADHD Therapeutics Market, Promising Pipeline Molecules, Heat Map 54
Figure 19: ADHD Therapeutics Market, Marketed Products, Heat Map, 2013 55
Figure 20: ADHD Therapeutics Market, Global, Treatment Patterns (million), 2013–2020 57
Figure 21: ADHD Therapeutics Market, Global, Market Size ($bn), 2013–2020 58
Figure 22: ADHD Therapeutics Market, Global, 2013–2020 59
Figure 23: ADHD Therapeutics Market, North America, Treatment Patterns, 2013–2020 60
Figure 24: ADHD Therapeutics Market, North America, Annual Cost of Treatment ($), 2013–2020 61
Figure 25: ADHD Therapeutics Market, North America, Market Size ($m), 2013–2020 62
Figure 26: ADHD Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2013–2020 63
Figure 27: ADHD Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020 64
Figure 28: ADHD Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013–2020 65
Figure 29: ADHD Therapeutics Market, Japan, 2013–2020 67
Figure 30: ADHD Therapeutics Market, Global, Major Licensing Deals by Year and Value, 2006–2014 70
Figure 31: ADHD Therapeutics Market, Global, Major Licensing Deals, 2006–2014 71
Figure 32: ADHD Therapeutics Market, Global, Major Co-developments Distribution, 2006–2014 72
Figure 33: ADHD Therapeutics Market, Global, Major Co-developments by Year and Phase, 2006–2014 73
To order this report: ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
Contact Clare: [email protected]
Intl: +1 339-368-6001
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
Sep. 24, 2016 04:30 PM EDT Reads: 1,473
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Sep. 24, 2016 04:30 PM EDT Reads: 1,662
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
Sep. 24, 2016 04:15 PM EDT Reads: 1,532
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Sep. 24, 2016 04:00 PM EDT Reads: 1,478
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
Sep. 24, 2016 03:45 PM EDT Reads: 1,397
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Sep. 24, 2016 03:00 PM EDT Reads: 1,012
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
Sep. 24, 2016 02:15 PM EDT Reads: 1,178
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Sep. 24, 2016 02:00 PM EDT Reads: 1,615
SYS-CON Events announced today that China Unicom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE F...
Sep. 24, 2016 01:30 PM EDT Reads: 1,668
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Sep. 24, 2016 01:00 PM EDT Reads: 1,467
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
Sep. 24, 2016 12:00 PM EDT Reads: 724
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Sep. 24, 2016 12:00 PM EDT Reads: 722
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Sep. 24, 2016 11:45 AM EDT Reads: 1,014
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
Sep. 24, 2016 11:15 AM EDT Reads: 1,444
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captu...
Sep. 24, 2016 11:00 AM EDT Reads: 940